Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on Oil Reservoir Analy

21 Jul 2008 07:00

RNS Number : 4429Z
ViaLogy PLC
21 July 2008
 



VIALOGY SHOWS EARLY SUCCESS IN OIL RESERVOIR ANALYSIS

London, July 21, 2008. ViaLogy PLC (LSE: VIY), announces completion of the initial phase of its pilot project with Atascosa Exploration LLC ("Atascosa") to apply its QuantumRD™ technology for geoseismic applications to determine the location and characteristics of underground oil deposits. 

With reference to a prospective Texas drilling site, the QuantumRD analysis confirmed the location of an oil trap, and mapped its size, shape, and predicted porosity. Atascosa estimates that this finding will save them over $500,000 by relocating the drill site to an optimal location some 700 feet from the site originally planned. In addition, ViaLogy's analysis discovered a second, deeper gas and oil trap of at least equal size. Work to drill both wells will begin in the coming weeks.

"We are very encouraged by ViaLogy's report, although final confirmation must await the results of drilling," said Atascosa CEO, John D. Mullins. "Our production engineering and geophysicist team is particularly impressed by the analysis tools Vialogy brings to bear in its novel approach to accurately characterizing reservoir prospects using existing datasets. We will look to grow our strategic collaboration with ViaLogy in analytical facets of reservoir modeling, water injection planning and enhanced recovery."

"The discovery of the new reservoir is remarkable, and could prove a significant find."

Atascosa confirmed that as payment for its QuantumRD work Vialogy is to receive a no-cost 5% working interest (WI), subject to existing agreements, royalty interest (RI), and overriding royalty interests (ORRI) in the wells drilled for each sand after payout of lease costs, geology, engineering, drilling, and other operational expenses. At each well payout, Atascosa will execute and deliver assignments to Vialogy sufficient to vest Vialogy with ownership of its 5% WI in the initial well in each sand and its right to participate in additional wells on the same basis as the other owners and as covered by the Operating Agreement.

The company estimates that this could produce approximately $8 million for Vialogy over the life of the wells. ViaLogy President and CEO Robert W. Dean stated; "We are very pleased to partner with Atascosa to commercialize our technology in the energy market. Atascosa's domain expertise will help us reach a broader problem and customer set. Geoseismology is an excellent vertical for us, as we will be able to realize a higher margin and performance premium for our disruptive technology. We are working with the Atascosa team to identify additional growth areas that we can address in the near-term."

For Further Information please contact:

ViaLogy Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807) Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 

Atascosa Exploration LLC

John D. Mullins, CEO (+1 210-402-3656)

Nominated Advisor Seymour Pierce Mark Percy +44 (0) 20-7107-8000 

PR Consultants - Redleaf Communications  Emma Kane / Samantha Robbins +44 (0) 20-7822-0200 

About ViaLogy: Network Centric Signal Processing.

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. Vialogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.vialogy.com. 

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSFWFIASASEFW
Date   Source Headline
1st Apr 201912:12 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSYourgene raises IONA® test awareness in Egypt
26th Feb 20193:21 pmRNSHolding(s) in Company
22nd Feb 201910:00 amEQSHardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020
22nd Feb 20198:05 amRNSHolding(s) in Company
19th Feb 20192:21 pmRNSHolding(s) in Company
19th Feb 20197:15 amEQSHardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
18th Feb 201910:59 amRNSIssue of Equity
18th Feb 20197:00 amRNSMajor Capital & Commercial Restructuring
8th Jan 20197:00 amRNSYourgene launches Sage 32 plex
3rd Dec 20187:00 amRNSHalf-year Results
7th Nov 20187:00 amRNSChange of Name to Yourgene Health plc
5th Nov 201811:24 amRNSShare Transfer
2nd Nov 20187:00 amRNSDirectorate Change
25th Oct 20183:30 pmRNSResult of AGM
25th Oct 20187:00 amRNSHolding(s) in Company
25th Oct 20187:00 amRNSAGM Statement
22nd Oct 20187:00 amRNSFurther re: Fundraise
12th Oct 20181:15 pmRNSAvailability of Research Commentary
12th Oct 20187:00 amRNSTrading Update and Notice of Results
5th Oct 20187:00 amRNSDirector's dealing and share option issue
4th Oct 20187:00 amRNS$1 million collaboration agreement
3rd Oct 20187:00 amRNSDirectorate change
2nd Oct 20187:00 amRNSNotice of AGM
1st Oct 201812:20 pmRNSResult of Fundraise
28th Sep 20185:41 pmRNSProposed fundraise to raise approximately £2.5m
28th Sep 20185:40 pmRNSFull year results and half-year trading update
25th Sep 201811:31 amRNSHolding(s) in Company
21st Sep 20184:10 pmRNSHolding(s) in Company
21st Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20189:30 amRNSSenior Appointment & Anticipated Director Change
19th Sep 201811:05 amRNSSecond Price Monitoring Extn
19th Sep 201811:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSLegal Settlement & Licence Agreement with Illumina
11th Sep 20187:00 amRNSHolding(s) in Company
7th Aug 201810:57 amRNSHolding(s) in Company
12th Jul 20187:00 amRNSShare option awards
4th Jul 20187:00 amRNSBoard Changes
26th Jun 20181:31 pmRNSCollaboration with Abnova
13th Jun 20187:00 amRNSOutstanding NIPS Solution Provider Award Win
11th Jun 20187:00 amRNSDNA sequencing technology development agreement
7th Jun 20183:44 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSPremaitha signs partnership agreement in India
4th Jun 201811:05 amRNSHolding(s) in Company
24th May 20187:00 amRNSHolding(s) in Company
18th May 20184:38 pmRNSHolding(s) in Company
18th May 201812:06 pmRNSHolding(s) in Company
18th May 201812:05 pmRNSHolding(s) in Company
18th May 20189:40 amRNSHoldings in Company
15th May 20187:00 amRNSPremaitha expands footprint with new laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.